1. Use of a pharmaceutical composition in the manufacture of a medicament for treating eosinophilic esophagitis in a subject, wherein the pharmaceutical composition comprises an extended-release composition that is formulated for prolonged release of a corticosteroid into esophageal tissue, and the medicament is to be locally administered to the subject.

2. The use according to claim 1, wherein the medicament is to be administered by injection into the esophageal tissue.

3. The use according to claim 1, wherein the medicament is to be administered by a plurality of injections into the esophageal tissue, such that at least two of the injections occur at different injection sites in the esophageal tissue.

4. The use according to any one of claims 1-3, wherein the medicament is to be administered by a plurality of injections into the esophageal tissue, such that at least two of the injections occur at injection sites located along a first ring of the esophagus defined by a circumference of the esophagus at a distance d1 above the gastroesophageal junction of the subject.

5. The use according to claim 4, wherein the distance d1 is at least 2 cm above the gastroesophageal junction.

6. The use according to claim 4 or 5, wherein the injection sites located along the first ring of the esophagus are situated equidistant relative to one another along the circumference of the first ring.

7. The use according to any one of claims 4-6, wherein at least two injections of the medicament into the esophageal tissue occur at injection sites located along a second ring of the esophagus defined by a circumference of the esophagus at a distance d2 above the gastroesophageal junction, wherein the distance d2 is greater than the distance d1.

8. The use according to claim 7, wherein the distance d2 is at least 1 cm greater than the distance d1.

9. The use according to claim 7 or 8, wherein the injection sites located along the second ring of the esophagus are situated equidistant relative to one another along the circumference of the second ring.

10. The use according to any one of claims 1-9, wherein the medicament is to be administered by a plurality of injections into the esophageal tissue, such that injections occur at injection sites located along a plurality of rings of the esophagus defined by respective circumferences of the esophagus at respective distances of the rings above the gastroesophageal junction of the subject, and wherein a pattern of injection sites within the esophagus is a spiral pattern with respect to a longitudinal axis of the esophagus.

11. The use according to any one of claims 1-10, wherein at least one injection of the medicament occurs into an area of esophageal inflammation.

12. The use according to any one of claims 1-11, wherein the medicament is to be administered by one or more injections into the esophageal tissue, such that each injection independently contains from 0.1 to 20 mg of the corticosteroid.

13. The use according to any one of clams 1-12, wherein the corticosteroid comprises a glucocorticoid agonist.

14. The use according to any one of claims 1-13, wherein the corticosteroid comprises at least one selected from the group consisting of desoxycorticosone, hydrocortisone, cortisone, methylprednisolone, prednisone, prednisolone, triamcinolone, dexamethasone, betamethasone, beclomethasone, beclomethasone-17,21-dipropionate, budesonide, flunisolide, fludrocortisone, mometasone, fluticasone, alclometasone, clocortolone, flurandrenolide, fluocinonide, hydrocortisone acetate, fluorometholone, fluocinolone acetonide, diflucortolone

valerate, paramethasone acetate, halcinonide, hydrocortisone phosphate, clobetasone butyrate, amcinonide, prednisolone succinate, and pharmaceutically acceptable salts and/or esters thereof.

15. The use according to any one of claims 1-14, wherein the corticosteroid comprises fluticasone or a pharmaceutically acceptable salt or ester thereof.

16. The use according to any one of claims 1-15, wherein the corticosteroid comprises fluticasone propionate.

17. The use according to any one of claims 1-16, wherein the corticosteroid is crystalline.

18. The use according to any one of claims 1-17, wherein the extended-release composition comprises the corticosteroid and a hydrophilic polymer.

19. The use according to any one of claims 1-18, wherein the extended-release composition comprises core-shell microparticles including:

(1) a crystalline drug core comprising one or more crystals of the corticosteroid; and

(2) a polymeric shell encapsulating the crystalline drug core, the polymeric shell being in contact but immiscible with the crystalline drug core,

and wherein a proportion of the crystalline drug core in the microparticles is more than 70% by weight relative to a total weight of the microparticles.

20. The use according to claim 18, wherein the crystalline drug core comprises 100% of the corticosteroid.

21. The use according to claim 19 or 20, wherein the polymeric shell comprises a hydrophilic polymer.

22. The use according to any one of claims 19-21, wherein the polymeric shell comprises one or more biodegradable polymers selected from the group consisting of a polyvinyl alcohol (PVA), an ethylene vinyl acetate(EVA), a poly(p-xylylene) polymer, a poly(lactic acid) (PLA), a poly(glycolic acid) (PGA), a poly(lactic-co-glycolic acid) (PLGA), a poly(ε-caprolactone) (PCL), a poly(valerolactone) (PVL), a poly(ε-decalactone) (PDL), a poly(1,4-dioxane-2,3-dione), a poly(1,3-dioxane-2-one), poly(para-dioxanone) (PDS), a poly(hydroxybutyric acid) (PHB), a poly(hydroxyvaleric acid) (PHV), and a poly(β-malic acid) (PMLA).

23. The use according to any one of claims 19-22, wherein the polymeric shell comprises a polyvinyl alcohol (PVA).

24. The use according to any one of claims 19-23, wherein the microparticles comprise 90-98% w/w of the crystalline drug core and 2-10% w/w of the polymeric shell.

25. The use according to any one of claims 1-24, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable vehicle comprising water and an excipient capable of suspending the extended-release composition in an aqueous medium.

26. The use according to claim 25, wherein the excipient is selected from the group consisting of a binder, a suspending agent, a disintegration agent, a filling agent, a surfactant, a solubilizer, a stabilizer, a lubricant, a wetting agent, a diluent, and combinations thereof.

27. The use according to claim 25 or 26, wherein the excipient is selected from the group consisting of a polysorbate, a polysaccharide, an acid salt, an alkali salt, a neutral salt and combinations thereof.

28. The used according to any one of claims 1-27, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable vehicle containing:

0.05 to 0.1% by weight of Polysorbate 80;

0.1 to 2.0% by weight of carboxymethylcellulose (CMC); and

0.1 to 2.0% by weight of sodium chloride, in sterile water, relative to a total weight of the pharmaceutically acceptable vehicle.

29. The use according to any one of claims 1-27, wherein the medicament and a topical agent are to be administered to the esophageal tissue, wherein the topical agent comprises an additional corticosteroid.

30. The use according to any one of claims 1-29, wherein the medicament is to be locally administered to the subject, followed by a subsequent injection of the medicament to the esophageal tissue of the subject.